| Title | Claps | Level | Year | L/Y |
|---|---|---|---|---|
|
Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T‐cell lymphoma
9 auth. U. Wollina, R. Dummer, N. Brockmeyer, H. Konrad, J. Busch, M. Kaatz, ...
In single center studies and case reports, it was shown that pegylated liposomal doxorubicin (PEG‐DOXO) was effective as second‐line therapy for patients with cutaneous T‐cell lymphoma (CTCL). The objective of this study was to evaluate the efficacy…
In single center studies and case reports, it was shown that pegylated liposomal doxorubicin (PEG‐DOXO) was effective as second‐line therapy for patients with cutaneous T‐cell lymphoma (CTCL). The objective of this study was to evaluate the efficacy and toxicity of single‐agent PEG‐DOXO as second‐line chemotherapy in patients with CTCL.
Published in
Cancer
|
13
|
7 | 2003 |
Social Media Posts